---
document_datetime: 2025-12-02 06:27:48
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/capecitabine-sun.html
document_name: capecitabine-sun.html
version: success
processing_time: 0.1087932
conversion_datetime: 2025-12-27 09:57:54.984241
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Capecitabine SUN

[RSS](/en/individual-human-medicine.xml/66172)

##### Withdrawn

This medicine's authorisation has been withdrawn

capecitabine Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 21 June 2016, the European Commission withdrew the marketing authorisation for Capecitabine SUN (capecitabine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Sun Pharmaceutical Industries Europe, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Capecitabine SUN was granted marketing authorisation in the EU on 21 June 2013 for the following indications:

- adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer. Capecitabine is indicated for the treatment of metastatic colorectal cancer.
- first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.
- in combination with docetaxel for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.

Previous therapy should have included an anthracycline. Capecitabine is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated. The marketing authorisation was initially valid for a 5-year period.

Capecitabine SUN is a generic medicine of Xeloda. There are other generic medicinal products of Xeloda authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Capecitabine SUN is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Capecitabine SUN : EPAR - Summary for the public

Reference Number: EMA/411926/2013

English (EN) (222.38 KB - PDF)

**First published:** 05/07/2013

**Last updated:** 22/12/2016

[View](/en/documents/overview/capecitabine-sun-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-312)

български (BG) (254.08 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/bg/documents/overview/capecitabine-sun-epar-summary-public_bg.pdf)

español (ES) (248.5 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/es/documents/overview/capecitabine-sun-epar-summary-public_es.pdf)

čeština (CS) (290.43 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/cs/documents/overview/capecitabine-sun-epar-summary-public_cs.pdf)

dansk (DA) (244.52 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/da/documents/overview/capecitabine-sun-epar-summary-public_da.pdf)

Deutsch (DE) (249.46 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/de/documents/overview/capecitabine-sun-epar-summary-public_de.pdf)

eesti keel (ET) (246.95 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/et/documents/overview/capecitabine-sun-epar-summary-public_et.pdf)

ελληνικά (EL) (314.14 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/el/documents/overview/capecitabine-sun-epar-summary-public_el.pdf)

français (FR) (392.42 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/fr/documents/overview/capecitabine-sun-epar-summary-public_fr.pdf)

hrvatski (HR) (407.1 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/hr/documents/overview/capecitabine-sun-epar-summary-public_hr.pdf)

italiano (IT) (222.28 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/it/documents/overview/capecitabine-sun-epar-summary-public_it.pdf)

latviešu valoda (LV) (294.08 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/lv/documents/overview/capecitabine-sun-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (274.65 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/lt/documents/overview/capecitabine-sun-epar-summary-public_lt.pdf)

magyar (HU) (267.46 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/hu/documents/overview/capecitabine-sun-epar-summary-public_hu.pdf)

Malti (MT) (298.35 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/mt/documents/overview/capecitabine-sun-epar-summary-public_mt.pdf)

Nederlands (NL) (248.78 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/nl/documents/overview/capecitabine-sun-epar-summary-public_nl.pdf)

polski (PL) (292.64 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/pl/documents/overview/capecitabine-sun-epar-summary-public_pl.pdf)

português (PT) (246.14 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/pt/documents/overview/capecitabine-sun-epar-summary-public_pt.pdf)

română (RO) (600.36 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/ro/documents/overview/capecitabine-sun-epar-summary-public_ro.pdf)

slovenčina (SK) (290.58 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/sk/documents/overview/capecitabine-sun-epar-summary-public_sk.pdf)

slovenščina (SL) (284.47 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/sl/documents/overview/capecitabine-sun-epar-summary-public_sl.pdf)

Suomi (FI) (244.44 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/fi/documents/overview/capecitabine-sun-epar-summary-public_fi.pdf)

svenska (SV) (244.67 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/sv/documents/overview/capecitabine-sun-epar-summary-public_sv.pdf)

## Product information

Capecitabine SUN : EPAR - Product Information

English (EN) (1.41 MB - PDF)

**First published:** 05/07/2013

**Last updated:** 22/12/2016

[View](/en/documents/product-information/capecitabine-sun-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-79)

български (BG) (866.21 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/bg/documents/product-information/capecitabine-sun-epar-product-information_bg.pdf)

español (ES) (1.51 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/es/documents/product-information/capecitabine-sun-epar-product-information_es.pdf)

čeština (CS) (1.87 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/cs/documents/product-information/capecitabine-sun-epar-product-information_cs.pdf)

dansk (DA) (1.42 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/da/documents/product-information/capecitabine-sun-epar-product-information_da.pdf)

Deutsch (DE) (1.62 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/de/documents/product-information/capecitabine-sun-epar-product-information_de.pdf)

eesti keel (ET) (1.59 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/et/documents/product-information/capecitabine-sun-epar-product-information_et.pdf)

ελληνικά (EL) (2.63 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/el/documents/product-information/capecitabine-sun-epar-product-information_el.pdf)

français (FR) (1.52 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/fr/documents/product-information/capecitabine-sun-epar-product-information_fr.pdf)

hrvatski (HR) (2.84 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/hr/documents/product-information/capecitabine-sun-epar-product-information_hr.pdf)

íslenska (IS) (1.42 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/is/documents/product-information/capecitabine-sun-epar-product-information_is.pdf)

italiano (IT) (1.57 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/it/documents/product-information/capecitabine-sun-epar-product-information_it.pdf)

latviešu valoda (LV) (2.06 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/lv/documents/product-information/capecitabine-sun-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.59 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/lt/documents/product-information/capecitabine-sun-epar-product-information_lt.pdf)

magyar (HU) (2 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/hu/documents/product-information/capecitabine-sun-epar-product-information_hu.pdf)

Malti (MT) (1.94 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/mt/documents/product-information/capecitabine-sun-epar-product-information_mt.pdf)

Nederlands (NL) (1.57 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/nl/documents/product-information/capecitabine-sun-epar-product-information_nl.pdf)

norsk (NO) (1.46 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/no/documents/product-information/capecitabine-sun-epar-product-information_no.pdf)

polski (PL) (1.9 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/pl/documents/product-information/capecitabine-sun-epar-product-information_pl.pdf)

português (PT) (1.52 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/pt/documents/product-information/capecitabine-sun-epar-product-information_pt.pdf)

română (RO) (1.97 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/ro/documents/product-information/capecitabine-sun-epar-product-information_ro.pdf)

slovenčina (SK) (2.02 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/sk/documents/product-information/capecitabine-sun-epar-product-information_sk.pdf)

slovenščina (SL) (1.8 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/sl/documents/product-information/capecitabine-sun-epar-product-information_sl.pdf)

Suomi (FI) (1.53 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/fi/documents/product-information/capecitabine-sun-epar-product-information_fi.pdf)

svenska (SV) (1.48 MB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/sv/documents/product-information/capecitabine-sun-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0007 21/06/2016

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Capecitabine SUN : EPAR - All Authorised presentations

English (EN) (140.36 KB - PDF)

**First published:** 05/07/2013

**Last updated:** 22/12/2016

[View](/en/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-70)

български (BG) (34.63 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/bg/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_bg.pdf)

español (ES) (143.72 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/es/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_es.pdf)

čeština (CS) (156.36 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/cs/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (143.41 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/da/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (143.45 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/de/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (143.55 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/et/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (171.62 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/el/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_el.pdf)

français (FR) (143.56 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/fr/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (291.72 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/hr/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (143.48 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/is/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_is.pdf)

italiano (IT) (143.45 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/it/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (175.98 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/lv/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (159.9 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/lt/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (161.07 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/hu/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (157.72 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/mt/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (143.46 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/nl/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (143.3 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/no/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_no.pdf)

polski (PL) (157 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/pl/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_pl.pdf)

português (PT) (143.43 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/pt/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_pt.pdf)

română (RO) (484.53 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/ro/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (156.52 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/sk/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (154.49 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/sl/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (144.55 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/fi/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (143.55 KB - PDF)

**First published:**

05/07/2013

**Last updated:**

22/12/2016

[View](/sv/documents/all-authorised-presentations/capecitabine-sun-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Capecitabine SUN Active substance capecitabine International non-proprietary name (INN) or common name capecitabine Therapeutic area (MeSH)

- Stomach Neoplasms
- Breast Neoplasms
- Colonic Neoplasms
- Colorectal Neoplasms

Anatomical therapeutic chemical (ATC) code L01BC06

### Pharmacotherapeutic group

capecitabine

### Therapeutic indication

Capecitabine is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes' stage-C) colon cancer.

Capecitabine is indicated for the treatment of metastatic colorectal cancer.

Capecitabine is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.

Capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Capecitabine is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

## Authorisation details

EMA product number EMEA/H/C/002050

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Sun Pharmaceutical Industries Europe B.V.

Polarisavenue 87

Marketing authorisation issued 21/06/2013 Withdrawal of marketing authorisation 21/06/2021 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Capecitabine SUN : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (201.15 KB - PDF)

**First published:** 29/08/2014

**Last updated:** 22/12/2016

[View](/en/documents/procedural-steps-after/capecitabine-sun-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Capecitabine SUN : EPAR - Public assessment report

Reference Number: EMA/370014/2013

English (EN) (536.35 KB - PDF)

**First published:** 05/07/2013

**Last updated:** 22/12/2016

[View](/en/documents/assessment-report/capecitabine-sun-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Capecitabine SUN

Adopted

Reference Number: EMA/CHMP/138360/2013

English (EN) (183.92 KB - PDF)

**First published:** 26/04/2013

**Last updated:** 22/12/2016

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-capecitabine-sun_en.pdf)

**This page was last updated on** 22/12/2016

## Share this page

[Back to top](#main-content)